TECHNETIUM TC-99M MEBROFENIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC-99M MEBROFENIN (TECHNETIUM TC-99M MEBROFENIN).
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
| Metabolism | Technetium Tc-99m mebrofenin is primarily taken up by hepatocytes and excreted unchanged into the bile. No significant metabolism occurs. |
| Excretion | Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose. |
| Half-life | Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion. |
| Protein binding | Approximately 90% bound to serum albumin and other plasma proteins. |
| Volume of Distribution | Approximately 0.3 L/kg, indicating distribution primarily within the extracellular fluid space and hepatobiliary system. |
| Bioavailability | Only administered intravenously; bioavailability is 100% by IV route; no oral bioavailability data as it is not administered orally. |
| Onset of Action | Intravenous: Visualization of the biliary tree occurs within 5-10 minutes; gallbladder visualization typically within 15-30 minutes post-injection. |
| Duration of Action | Biliary excretion continues for up to 24 hours; imaging acquisitions are usually completed within 1-2 hours. Delayed images may be obtained at 24 hours if needed. |
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
| Dosage form | INJECTABLE |
| Renal impairment | No dosage adjustment required for impaired renal function; drug is primarily hepatobiliary excreted. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); consider alternative imaging. For Child-Pugh class B, use lowest effective dose (1 mCi) with extended imaging protocol. |
| Pediatric use | Children: 0.05 mCi/kg (0.05 mCi/kg, minimum 0.5 mCi) IV, not to exceed 5 mCi total. |
| Geriatric use | No specific dose adjustment required; use lowest effective dose (1-2 mCi) due to potential comorbidities and prolonged imaging time. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC-99M MEBROFENIN (TECHNETIUM TC-99M MEBROFENIN).
| Breastfeeding | Technetium-99m has a physical half-life of 6.02 hours. In breast milk, activity peaks at 2-12 hours. The milk-to-plasma ratio for Tc-99m mebrofenin is not specifically reported but for Tc-99m pertechnetate M/P ratio is 4.5. For mebrofenin, assumed similar. Interruption of breastfeeding for 24-48 hours after administration is recommended. Complete cessation may be considered, but minimal risk after 48 hours. |
| Teratogenic Risk | Technetium TC-99M mebrofenin is a radiopharmaceutical. Fetal radiation exposure depends on gestational stage. First trimester: highest risk of teratogenesis, including CNS malformations and growth restriction, with a threshold of approximately 100 mGy. Second and third trimesters: increased risk of childhood cancer with a linear no-threshold model. Estimated fetal dose for a typical 185 MBq (5 mCi) administration is ~10 mGy, below the 100 mGy threshold for malformations, but attributable risk for childhood leukemia is estimated at 1 in 6000. All trimesters: consider alternative imaging without ionizing radiation when possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to technetium Tc-99m mebrofenin or any component of the formulation"]
| Precautions | ["Radioactive material; use appropriate shielding and handling precautions","Risk of allergic or hypersensitivity reactions","Caution in patients with severe hepatic impairment as scan quality may be compromised","Use in pregnancy only if clearly needed; consider risk to fetus","Lactation: interrupt breastfeeding for a period adequate to allow decay of radioactivity"] |
Loading safety data…
| Fetal Monitoring | No specific maternal monitoring required beyond standard radiopharmaceutical safety. Confirm pregnancy status before administration. Ensure adequate hydration to promote renal clearance and reduce radiation dose. Monitor for allergic reactions (rare). Fetal monitoring: no specific intervention needed, but discuss risks with patient. |
| Fertility Effects | Single diagnostic dose of Tc-99m mebrofenin does not adversely affect fertility. Gonadal radiation dose from a typical 185 MBq administration is approximately 0.02 mGy, far below the threshold for inducing infertility. No known effect on oogenesis or spermatogenesis. |